🔗 Share this article

Chancellor Rachel Reeves has announced she is preparing "focused measures to deal with cost of living issues" in the forthcoming financial statement.

During an interview with the BBC, she stated that lowering price rises is a collective duty of both the administration and the central bank.

The United Kingdom's price growth is expected to be the highest among the Group of Seven developed nations this year and the following year.

Possible Utility Bill Measures

Sources suggest the administration could intervene to bring down energy bills, such as by slashing the current 5% level of VAT charged on energy supplies.

Another option is to reduce some of the policy costs presently included in household expenses.

Fiscal Limitations and Expert Expectations

The government will obtain the next assessment from the independent fiscal watchdog, the Office for Budget Responsibility, on Monday, which will clarify how much room there is for these measures.

The expectation from the majority of analysts is that the Chancellor will have to introduce tax rises or expenditure reductions in order to fulfill her voluntary borrowing rules.

Previously on Thursday, calculations indicated there was a £22 billion shortfall for the Treasury chief to fill, which is at the more modest range of expectations.

"It is a joint responsibility between the central bank and the administration to continue tackling some of the causes of price increases," Reeves told the BBC in the US capital, at the annual meetings of the International Monetary Fund and World Bank.

Revenue Commitments and Global Issues

While much of the attention has been on likely tax increases, the chancellor said the latest information from the OBR had not changed her vow to campaign commitments not to raise tax levels on income tax, VAT or social security contributions.

She blamed an "uncertain global environment" with growing geopolitical and trade tensions for the Budget revenue measures, probably to be directed on those "with the broadest shoulders."

Global Economic Disputes

Commenting on apprehensions about the UK's economic relations with the Asian nation she said: "The UK's security interests invariably are paramount."

Recent announcement by China to tighten export controls on critical minerals and other resources that are key for high-technology manufacturing led US President Donald Trump to propose an further 100% tariff on goods from the Asian country, raising the prospect of an full-scale trade war between the two economic giants.

The American finance chief called the Chinese decision "economic coercion" and "a global supply chain power grab."

Asked about considering the American proposal to join its conflict with China, the Chancellor said she was "very concerned" by Chinese actions and urged the Chinese government "not to put up barriers and restrict access."

She said the action was "damaging for the global economy and creates additional obstacles."

"It is my opinion there are areas where we should confront China, but there are also valuable chances to sell into Chinese markets, including banking sector and other areas of the economy. We've got to maintain that balance appropriate."

The chancellor also stated she was collaborating with international partners "on our own essential resources plan, so that we are less reliant."

NHS Drug Costs and Investment

Reeves also admitted that the price the NHS spends on pharmaceuticals could rise as a result of current discussions with the US government and its pharmaceutical firms, in return for lower tariffs and funding.

A number of the biggest global pharmaceutical manufacturers have said recently that they are either delaying or scrapping investments in the United Kingdom, with several blaming the modest returns they are receiving.

Recently, the Science Minister said the price the health service pays for drugs would need to increase to halt companies and pharmaceutical investment departing from the United Kingdom.

The Chancellor informed media: "It has been observed due to the payment system, that clinical trials, innovative medicines have not been provided in the UK in the manner that they are in other European countries."

"The objective is to guarantee that individuals getting treatment from the NHS are can receive the top life-saving treatments in the globe. And so we are reviewing all of that, and... seeking to secure increased investment into the UK."